NovaBridge Biosciences (NBP) Accumulated Depreciation & Amortization (2021 - 2023)

NovaBridge Biosciences (NBP) has reported Accumulated Depreciation & Amortization for 3 consecutive years, with $5.1 billion the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Accumulated Depreciation & Amortization fell 40.72% year-over-year to $5.1 billion; the trailing twelve-month figure through Dec 2023 stood at $5.1 billion (down 40.72% YoY), and the FY2023 full-year result was $5.1 billion, down 40.72% from the prior year.
• Accumulated Depreciation & Amortization eased to $5.1 billion in Q4 2023 per NBP's latest filing, from $8.5 billion in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.5 billion in Q4 2022 to a low of $5.1 billion in Q4 2023.
• Median Accumulated Depreciation & Amortization over the past 3 years was $7.1 billion (2021), compared with a mean of $6.9 billion.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation & Amortization rose 19.64% — and 2023, when it plunged 40.72%.
• A 3-year view of Accumulated Depreciation & Amortization shows it stood at $7.1 billion in 2021, then grew by 19.64% to $8.5 billion in 2022, then plunged by 40.72% to $5.1 billion in 2023.
• Per Business Quant, the three latest NBP Accumulated Depreciation & Amortization figures stand at $5.1 billion (Q4 2023), $8.5 billion (Q4 2022), and $7.1 billion (Q4 2021).